Sculati Wealth Management
VRTX icon

Sculati Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Sculati Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.6M Buy
3,154
+8
+0.3% +$4.1K 0.52% 55
2026
Q2 		$1.53M Sell
3,146
-134
-4% -$59.4K 0.51% 53
2026
Q1 		$1.46M Sell
3,280
-80
-2% -$37.3K 0.54% 55
2025
Q4 		$1.52M Buy
3,360
+32
+1% +$13.8K 0.54% 54
2025
Q3 		$1.3M Buy
3,328
+149
+5% +$62.3K 0.46% 59
2025
Q2 		$1.42M Buy
3,179
+242
+8% +$112K 0.53% 57
2025
Q1 		$1.42M Buy
2,937
+381
+15% +$178K 0.58% 49
2024
Q4 		$1.03M Buy
2,556
+25
+1% +$11.6K 0.41% 59
2024
Q3 		$1.18M Buy
2,531
+579
+30% +$278K 0.47% 58
2024
Q2 		$915K Buy
1,952
+507
+35% +$220K 0.39% 61
2024
Q1 		$604K Buy
+1,445
New +$611K 0.26% 72

Other funds holding VRTX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Sculati Wealth Management's VRTX Position: Q3 2026 in Review

Sculati Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.25% in Q3 2026, buying an estimated $4.1K and bringing the position to 3,154 shares worth $1.6M. The position accounts for 0.52% of the portfolio, ranked #55.

Sculati Wealth Management first reported a position in VRTX in Q1 2024 and has held it in 11 quarters since. 1,004 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Sculati Wealth Management held 3,154 shares of Vertex Pharmaceuticals worth $1.6M as of Q3 2026.
  • Sculati Wealth Management bought 8 Vertex Pharmaceuticals shares in Q3 2026, an estimated $4.1K.
  • Vertex Pharmaceuticals made up 0.52% of Sculati Wealth Management's portfolio in Q3 2026, its #55 holding.
  • Sculati Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 11 quarters since.
  • 1,004 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Sculati Wealth Management's 13F filing for Q3 2026, filed 19 Oct 2026.